Serina Therapeutics Inc (SER)

$3.10 +0.41 (15.24%)
Market Cap 28.69M
Revenue (ttm) 60,000.00
Net Income (ttm) -11.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18,566.67%
Debt to Equity Ratio 0.00
Volume 156,600
Avg Vol 52,268
Day's Range N/A - N/A
Shares Out 10.66M
Stochastic %K 91%
Beta 1.15
Analysts Strong Sell
Price Target $13.00

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which...

Industry: Biotechnology
Sector: Healthcare
Phone: 256 327 9630
Address:
601 Genome Way, Suite 2001, Huntsville, United States
WarpedHitbox
WarpedHitbox Jan. 17 at 12:44 AM
{} @CoralSharkie operating on another level 🧠❄️ {} Cold vision, real substance. .Not following yet? That’s on you. Free game, unreal value~ 🐐 $TLSA $SBEV $SER $JFB <<>> On close watch as well….
0 · Reply
PaulLaurent
PaulLaurent Jan. 16 at 7:08 AM
🚀📈 Top Gainers 📈🚀 AH $CGTL $SLGB $RDGT $VTVT $SER
0 · Reply
JohnTrack
JohnTrack Jan. 15 at 9:36 PM
$SER quick spark in headlines... https://www.rapidticker.com/news/ser-sec-filing-b4caf6
0 · Reply
garygb
garygb Jan. 11 at 5:49 PM
$SER Buying opportunity
1 · Reply
StockScanners
StockScanners Jan. 10 at 4:27 AM
$SER reached 3
0 · Reply
www_larval_com
www_larval_com Jan. 8 at 2:52 PM
Dufus here, $SER just turned -5% lower to 9% (~193Kv) a few minutes ago, follow for more volatility.
0 · Reply
topstockalerts
topstockalerts Jan. 8 at 1:31 PM
$SER there it goes… 💪
0 · Reply
StockScanners
StockScanners Jan. 8 at 7:14 AM
$SER keep watch if this holds above 2.50
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jan. 8 at 4:53 AM
🌅 Watchlist part 1 ✅ $IMG mid $1.50 support; if above $1.70, potential to $2.00 – $2.30 ✅ $NVVE low $4.00 support; if above $4.70, potential to $5.00 – $5.50 ✅ $ECDA mid $0.50 support; if above $0.65, potential to $0.80 – $1.00 ✅ $SER mid $2.50 support; if above $3.00, potential to $3.20 – $3.50 ✅ $ABVE $2.50 support; if above $3.00, potential to $3.20 – $3.40 🚨 These tickers are not ideal for swing accumulation at current prices 🚨 ✅ Ideal long entry near established support 🎯 Use a stop loss if price falls below support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
JTTrader
JTTrader Jan. 8 at 4:45 AM
$SER Hopefully the FDA hold is released soon.
0 · Reply
Latest News on SER
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Jan 15, 2026, 4:30 PM EST - 1 day ago

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Dec 11, 2025, 4:15 PM EST - 5 weeks ago

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Dec 10, 2025, 4:30 PM EST - 5 weeks ago

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 13, 2025, 6:10 AM EST - 2 months ago

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Nov 3, 2025, 6:05 AM EST - 2 months ago

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Oct 8, 2025, 11:00 AM EDT - 3 months ago

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Oct 6, 2025, 4:15 PM EDT - 3 months ago

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 9, 2025, 3:20 PM EDT - 4 months ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 6:00 AM EDT - 4 months ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 25, 2025, 4:15 PM EDT - 5 months ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 11, 2025, 4:30 PM EDT - 5 months ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 29, 2025, 6:44 AM EDT - 6 months ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 28, 2025, 6:00 AM EDT - 6 months ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 10, 2025, 4:10 PM EDT - 6 months ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jul 1, 2025, 4:15 PM EDT - 7 months ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 23, 2025, 7:24 PM EDT - 7 months ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 8:30 PM EDT - 7 months ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 7 months ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Jun 9, 2025, 4:05 PM EDT - 7 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025, 4:50 PM EDT - 8 months ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025, 3:15 PM EDT - 8 months ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025, 4:23 PM EDT - 9 months ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 29, 2025, 6:00 AM EDT - 9 months ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 15, 2025, 6:30 AM EDT - 9 months ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 8, 2025, 4:30 PM EDT - 10 months ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Apr 7, 2025, 6:30 AM EDT - 10 months ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:30 PM EDT - 10 months ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Mar 24, 2025, 6:30 AM EDT - 10 months ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 12, 2025, 4:15 PM EST - 1 year ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Feb 3, 2025, 4:30 PM EST - 1 year ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 15, 2025, 4:05 PM EST - 1 year ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Jan 14, 2025, 5:25 PM EST - 1 year ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 16, 2024, 6:00 AM EST - 1 year ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Dec 11, 2024, 6:05 AM EST - 1 year ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Dec 2, 2024, 5:22 PM EST - 1 year ago

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 12, 2024, 5:00 PM EST - 1 year ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 6:42 PM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Aug 9, 2024, 4:15 PM EDT - 1 year ago

Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Jul 18, 2024, 5:00 PM EDT - 1 year ago

Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 14, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

Mar 26, 2024, 5:04 PM EDT - 1 year ago

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Mar 22, 2024, 5:27 PM EDT - 1 year ago

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

Feb 27, 2024, 3:19 PM EST - 2 years ago

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

Aug 30, 2023, 7:00 AM EDT - 2 years ago

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:05 PM EDT - 2 years ago

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

WarpedHitbox
WarpedHitbox Jan. 17 at 12:44 AM
{} @CoralSharkie operating on another level 🧠❄️ {} Cold vision, real substance. .Not following yet? That’s on you. Free game, unreal value~ 🐐 $TLSA $SBEV $SER $JFB <<>> On close watch as well….
0 · Reply
PaulLaurent
PaulLaurent Jan. 16 at 7:08 AM
🚀📈 Top Gainers 📈🚀 AH $CGTL $SLGB $RDGT $VTVT $SER
0 · Reply
JohnTrack
JohnTrack Jan. 15 at 9:36 PM
$SER quick spark in headlines... https://www.rapidticker.com/news/ser-sec-filing-b4caf6
0 · Reply
garygb
garygb Jan. 11 at 5:49 PM
$SER Buying opportunity
1 · Reply
StockScanners
StockScanners Jan. 10 at 4:27 AM
$SER reached 3
0 · Reply
www_larval_com
www_larval_com Jan. 8 at 2:52 PM
Dufus here, $SER just turned -5% lower to 9% (~193Kv) a few minutes ago, follow for more volatility.
0 · Reply
topstockalerts
topstockalerts Jan. 8 at 1:31 PM
$SER there it goes… 💪
0 · Reply
StockScanners
StockScanners Jan. 8 at 7:14 AM
$SER keep watch if this holds above 2.50
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading Jan. 8 at 4:53 AM
🌅 Watchlist part 1 ✅ $IMG mid $1.50 support; if above $1.70, potential to $2.00 – $2.30 ✅ $NVVE low $4.00 support; if above $4.70, potential to $5.00 – $5.50 ✅ $ECDA mid $0.50 support; if above $0.65, potential to $0.80 – $1.00 ✅ $SER mid $2.50 support; if above $3.00, potential to $3.20 – $3.50 ✅ $ABVE $2.50 support; if above $3.00, potential to $3.20 – $3.40 🚨 These tickers are not ideal for swing accumulation at current prices 🚨 ✅ Ideal long entry near established support 🎯 Use a stop loss if price falls below support 🚨 Avoid chasing long into strength near resistance 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
JTTrader
JTTrader Jan. 8 at 4:45 AM
$SER Hopefully the FDA hold is released soon.
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 8 at 3:57 AM
Updated gappers in after hours trading $IMG $NVVE $ECDA $SER $ABVE Enjoy your evening!
0 · Reply
BearTamerTrading
BearTamerTrading Jan. 8 at 3:12 AM
We also secured profits on the following tickers: $JCSE $SER $IMG $AXTI $LUCY and so many more! Proof in the post below ⬇️ Congratulations everyone.
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 8 at 12:25 AM
Gappers here in after hours trading $IMG $NVVE $SER $ECDA $PMCB I'll update later this evening.
0 · Reply
robiein35
robiein35 Jan. 8 at 12:22 AM
$SER may be . Don’t think any BO since many insider sell transactions at low price.
0 · Reply
Parabolicsuperman
Parabolicsuperman Jan. 7 at 11:45 PM
$SER possible NDA news or clinical data
0 · Reply
Uchiha_Boruto
Uchiha_Boruto Jan. 7 at 11:24 PM
$SER yeah took also the 2 min and out 🤑 BANG 💥 🫡
0 · Reply
Parabolicsuperman
Parabolicsuperman Jan. 7 at 11:21 PM
$SER something big might have got leaked
0 · Reply
Parabolicsuperman
Parabolicsuperman Jan. 7 at 11:18 PM
$SER something is coming and big
1 · Reply
Bagstand204
Bagstand204 Jan. 7 at 11:18 PM
$SER Somebody knows something it seems...
0 · Reply
GoodGoyim
GoodGoyim Jan. 7 at 11:18 PM
$SER WHAT IS THE NEWS?
0 · Reply
chrisusm
chrisusm Jan. 7 at 10:52 PM
$SER In 2.70
0 · Reply
Parabolicsuperman
Parabolicsuperman Jan. 7 at 10:43 PM
$SER
0 · Reply